ArticleVeterinary dermatology2026
Treatment of Reactive Histiocytosis With Oclacitinib: A Retrospective Case Series of 10 Dogs.
Article in Veterinary dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cutaneous Reactive Histiocytosis in Golden Retrievers: An Immunohistochemical Approach.Veterinary dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCanine reactive histiocytosis is a proliferative disorder of activated interstitial dendritic cells with cutaneous and systemic forms. An immune-mediated aetiology is likely, and systemic immunomodulatory agents such as corticosteroids, tetracycline/niacinamide, ciclosporin, azathioprine and leflunomide have been employed for its management. HYPOTHESIS/
objectivesThe aim of this retrospective case series is to report the clinical features and therapeutic response to oclacitinib in dogs with reactive histiocytosis. ANIMALS: Ten privately owned dogs. MATERIALS AND
methodsAll dogs were diagnosed with reactive histiocytosis based on compatible clinical history, skin lesions and histopathological features, and were treated with oclacitinib as a sole therapy. Immunohistochemical investigation was used to characterise dermal cellular infiltrates for eight of 10 dogs. Clinical features and case outcomes are summarised.
resultsAll 10 dogs presented with dermal nodules and/or erythematous plaques affecting the head, trunk or limbs; four dogs also had documented or suspected involvement of the nasal or oral cavities. Seven dogs had been treated previously with one or more immunomodulatory agents without durable disease control. All dogs were completely responsive to treatment with oclacitinib, at or slightly above the standard antipruritic dosage. Skin and mucosal lesions resolved within 2-12 weeks. Lesion remission was maintained with oclacitinib monotherapy for varying follow-up times, although four dogs had brief recurrences addressed with adjustments in oclacitinib dosing. CONCLUSIONS AND CLINICAL RELEVANCE: Although reactive histiocytosis can have a naturally waxing and waning course, oclacitinib appears to be rapidly effective for management, even in cases refractory to other immunomodulatory agents or with involvement of the oral or nasal cavities. ANIMAL USE STATEMENT: Animal use was conducted in accordance with the international, national and institutional guidelines for the humane treatment of animals, and with relevant legislation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.